Moderna's investigational therapeutic for methylmalonic acidemia (mrna-3705) selected by u.s. food & drug administration for start pilot program

Center for biologics evaluation and research has chosen mrna-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases cambridge, ma / accesswire / june 6, 2024 / moderna, inc. (nasdaq:mrna) today announced that the u.s. food and drug administration (fda) has selected mrna-3705 for the support for clinical trials advancing rare disease therapeutics (start) pilot program. mrna-3705 is an investigational therapeutic for methylmalonic acidemia (mma) due to methylmalonic-coa mutase (mut) deficiency.
MRNA Ratings Summary
MRNA Quant Ranking